US Patent

US10441194 — Ingestible event marker systems

Formulation · Assigned to Proteus Digital Health Inc · Expires 2029-07-26 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects ingestible event marker systems that include an ingestible marker and a personal signal receiver for tracking internal physiological events.

USPTO Abstract

Ingestible event marker systems that include an ingestible event marker (i.e., an IEM) and a personal signal receiver are provided. Embodiments of the IEM include an identifier, which may or may not be present in a physiologically acceptable carrier. The identifier is characterized by being activated upon contact with a target internal physiological site of a body, such as digestive tract internal target site. The personal signal receiver is configured to be associated with a physiological location, e.g., inside of or on the body, and to receive a signal the IEM. During use, the IEM broadcasts a signal which is received by the personal signal receiver.

Drugs covered by this patent

Patent Metadata

Patent number
US10441194
Jurisdiction
US
Classification
Formulation
Expires
2029-07-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Proteus Digital Health Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.